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ScOur scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However,
despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few
multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing
multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical
evaluation of patientswith BP. Common terms and end points of BP are needed so that experts in the field can
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2 years of collaborative efforts to attainmutually acceptable commondefinitions forBPandproposes a disease
extent score, the BPDisease Area Index. These items should assist in the development of consistent reporting
of outcomes in future BP reports and studies. ( J Am Acad Dermatol 2012;66:479-85.)
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d It is impossible to compare the
therapeutic outcomes from the majority
of bullous pemphigoid studies using
meta-analysis, as they have varying
definitions and outcome measures.
d These recommendations, developed
over the last 3 years by experts, provide
appropriate definitions for the various
stages of disease activity and therapeutic
end points in bullous pemphigoid.
d These definitions can be used in case
series and clinical trials to compare the
efficacy of treatments for bullous
pemphigoid.Bullous pemphigoid (BP)
is a common autoimmune
bullous disease typically af-
fecting the elderly. There
have been only a handful of
well-designed randomized
controlled trials assessing
the effectiveness of therapies
for BP.1 In relatively rare
diseases where it is difficult
to include enough patients to
have sufficient power to
compare different treat-
ments, meta-analysis is a
powerful tool that is used to
pool data across trials.
However, it is impossible to
compare the therapeutic out-
comes from the majority of
these BP studies using meta-analysis, as they have
varying definitions and outcome measures.
PURPOSE
The purpose of this statement is to provide
appropriate definitions for the various stages of
disease activity, define therapeutic end points in
BP, and to propose an objective disease extent
measure that can be used in clinical trials. The use
of the same definitions and outcome measures
makes the results of trials more comparable. Since
definitions and outcome measures for pemphigus2-4
have been published, most trials in pemphigus and
reports have begun adopting these systems or refer-
ring to them when their existing trials using other
measures were unable to show a difference.5
METHODS
An international BP definitions committee was
organized in 2008, at the point when the international
pemphigus definitions committee completed its sim-
ilar work on pemphigus.2 The committee was an
expansion of the first committee and convened 7
times over 2 years to discuss the appropriate defini-
tions. These meetings were held at the American
Academy of Dermatology (AAD) annual meeting in
San Antonio, TX, in 2009 (D. F. M. and V. P. W.);
European Society for Dermatologic Research inBudapest, Hungary, in 2009
(D. F. M. and P. J.); the
European Academy of Der-
matovenereology in Berlin,
Germany, in 2009 (D. F. M.
and L. B.); the AAD in Miami,
FL, in 2010 (D.F.M. and V. P.
W.); the Pemphigus 2010
Meeting in Bern, Switzerland
(V. P.W. andD. F.M.); and the
International Pemphigus and
Pemphigoid Meeting at the
National Institutes of Health
in November 2010 (V. P. W.
and D. F. M.), in Bethesda,
MD. The final meeting was
held at the AAD in 2011 in
NewOrleans, LA (D. F.M. and
V. P. W.). Meetings were sup-ported in part by local dermatology societies. The
draft definitions and end points were electronically
mailed to the larger group, allowing for comments
between meetings.THE RECOMMENDATIONS
Observation points
The end points are illustrated and summarized
(Fig 1 and Table I).Early end points
‘‘Baseline’’ is the point at which a physician starts
treatment for BP.
‘‘Control of disease activity’’ (disease control;
beginning of consolidation phase) is defined as the
point at which new lesions or pruritic symptoms
cease to form and established lesions begin to heal.
The time to disease control is the time between
baseline and this control point.
‘‘End of the consolidation phase’’ is defined as the
time at which no new lesions or pruritic symptoms
have developed for a minimum of 2 weeks and the
majority (approximately 80%) of established lesions
has healed. At this point tapering of corticosteroids
often occurs. The length of the consolidation phase
is the time between disease control and the end of
consolidation phase.
Abbreviations used:
AAD: American Academy of Dermatology
BP: bullous pemphigoid
BPDAI: Bullous Pemphigoid Disease Area Index
DAI: Disease Area Index
PDAI: Pemphigus Disease Area Index
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within 1 week or pruritus lasting less than a week
and clearing without treatment.
‘‘Nontransient lesions’’ are new lesions that do not
heal within 1 week or pruritus continuing more than
a week with or without treatment.
Intermediate end points
During this period, the corticosteroids and other
treatments are usually being tapered, but for some
patients medication doses do not change because
of flaring with attempts to taper treatment.
‘‘Complete remission during tapering’’ is the ab-
sence of nontransient lesions while the patient is
receiving more than minimal therapy. There is no
minimum time point here as the patient is under
control but has not yet reached the desired out-
come of disease remission on minimal or no
therapy.
Late observation end points
Late observation end points of disease activity are
identified as: (1) complete remission off therapy; and
(2) complete remission on therapy, both of which
only apply to patients who have had no new or
established lesions for at least 2 months. ‘‘Complete
remission off therapy’’ is defined as an absence of
new or established lesions or pruritic symptoms
while the patient is off all BP therapy for at least 2
months.Fig 1. Pictorial depiction of end p‘‘Complete remission on therapy’’ is defined as
the absence of new or established lesions or
pruritus while the patient is receiving minimal
therapy for at least 2 months. ‘‘Minimal therapy’’
is defined as less than or equal to 0.1 mg/kg/d
of prednisone (or the equivalent) or 20 g/wk
of clobetasol propionate and/or minimal adju-
vant or maintenance therapy for at least 2
months, as shown in Fig 1 and discussed further
below.
Minimal adjuvant therapy in BP corresponds to
the following doses or less: methotrexate 5 mg/wk;
azathioprine 0.7 mg/kg/d (with normal thiopurine
s-methyltransferase level); mycophenolate mofetil
500 mg/d; mycophenolic acid 360 mg/d; or dapsone
50 mg/d. There has only been one small randomized
controlled trial on tetracycline and niacinamide,6
which was underpowered because of low numbers
and was unable to demonstrate a difference.
Nevertheless, the committee’s expert opinion is
that full therapeutic doses of the tetracyclines may
work in localized forms of BP. As the tetracycline
class of drugs is relatively nontoxic, the full thera-
peutic dose was listed among minimal therapies
for BP.
‘‘Partial remission off therapy’’ is defined as the
presence of transient new lesions that heal within
1 week without treatment and while the patient is off
all BP therapy for at least 2 months.
‘‘Partial remission on minimal therapy’’ is defined
as the presence of transient new lesions that heal
within 1 week while the patient is receiving minimal
therapy.
A newer term, ‘‘mild new activity,’’ refers to
fewer than 3 lesions a month (blisters, eczematous
lesions, or urticarial plaques) that do not heal
within 1 week, or the extension of established
lesions or pruritus once per week but less thanoints in bullous pemphigoid.
Table I. Definitions for bullous pemphigoid
Early observation points
Baseline Day that BP therapy is started by physician
Control of disease activity Time at which new lesions cease to form and established lesions begin to heal or
pruritic symptoms start to abate
Time to control of disease activity
(disease control; beginning of
consolidation phase)
Time interval from baseline to control of disease activity
End of consolidation phase Time at which no new lesions have developed for minimum of 2 wk and
approximately 80% of lesions have healed and pruritic symptoms are minimal
Intermediate observation end points
Transient lesions New lesions that heal within 1 wk or pruritus lasting\1 wk and clearing without
treatment
Nontransient lesions New lesions that do not heal within 1 wk or pruritus continuing[1 wk with or
without treatment
Complete remission during tapering Absence of nontransient lesions while patient is receiving more than minimal
therapy
Late observation end points
Minimal therapy # 0.1 mg/kg/d Of prednisone (or equivalent) or 20 g/wk of clobetasol propionate
and/or minimal adjuvant or maintenance therapy
Minimal adjuvant therapy and/or
maintenance therapy
Following doses or less: methotrexate 5 mg/wk; azathioprine 0.7 mg/kg/d (with
normal thiopurine s-methyltransferase level); mycophenolate mofetil 500 mg/d;
mycophenolic acid 360 mg/d; or dapsone 50 mg/d
Partial remission on minimal therapy Presence of transient new lesions that heal within 1 wk while patient is receiving
minimal therapy for at least 2 mo
Complete remission on minimal
therapy
Absence of new or established lesions or pruritus while patient is receiving
minimal therapy for at least 2 mo
Partial remission off therapy Presence of transient new lesions that heal within 1 wk without treatment while
patient is off all BP therapy for at least 2 mo
Complete remission off therapy Absence of new or established lesions or pruritus while patient is off all BP therapy
for at least 2 mo
Mild new activity \3 Lesions/mo (blisters, eczematous lesions, or urticarial plaques) that do not heal
within 1 wk, or extension of established lesions or pruritus once/wk but less than
daily in patient who has achieved disease control; these lesions have to heal
within 2 wk
Relapse/flare Appearance of $ 3 new lesions/mo (blisters, eczematous lesions, or urticarial
plaques) or at least one large ([10 cm diameter) eczematous lesion or urticarial
plaques that do not heal within 1 wk, or extension of established lesions or daily
pruritus in patient who has achieved disease control
Failure of therapy for initial control Development of new nontransient lesions or continued extension of old lesions, or
failure of established lesions to begin to heal or continued pruritus despite:
Clobetasol propionate 40 g/d for 4 wk; or
Prednisone 0.75 mg/kg/d equivalent for minimum of 3 wk with or without drugs
used for maintenance therapy; or
A tetracycline on full dosing for 4 wk; or
Dapsone 1.5 mg/kg/d for 4 wk; or
Methotrexate 15 mg/wk (if[60 kg and no major renal impairment) for 4 wk; or
Azathioprine 2.5 mg/kg/d for 4 wk (if thiopurine s-methyltransferase level is
normal); or
Mycophenolate mofetil 40 mg/kg/d (if normal renal function, otherwise according
to age/creatinine clearance) for 4 wk
BP, Bullous pemphigoid.
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This term was not included in the pemphigus
definitions but the committee thought that it might
be important to capture this phase during studies to
determine if some patients with BP and certaincharacteristics or treatments experienced new mild
activity not significant enough to constitute a flare.
In this way, it could be determined in the future if
these patients with BP might benefit from a change
of treatment plan or not.
Fig 2. Subjective Bullous Pemphigoid (BP) Disease Area
Index (BPDAI ) pruritus score. VAS, Visual analog scale.
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The terms ‘‘relapse’’ and ‘‘flare’’ are used inter-
changeably and are defined as the appearance of
3 or more new lesions a month (blisters, eczema-
tous lesions, or urticarial plaques) or at least one
large ([10 cm diameter) eczematous lesion or
urticarial plaque that does not heal within 1 week,
or the extension of established lesions or daily
pruritus in a patient who has achieved disease
control.
Treatment failure
‘‘Failure of therapy for initial control’’ is defined as
the development of new nontransient lesions or
continued extension of old lesions, or failure of
established lesions to begin to heal or daily pruritus
despite certain strengths of corticosteroids with or
without higher doses of adjuvants. The dose of
prednisone defined as treatment failure is 0.75
mg/kg/d equivalent for minimum of 3 weeks. This
dose was selected because the Cochrane review of
interventions for BP1,7 determined that in acute BP
there was no purpose in using prednisone at a higher
dose than this. Topical clobetasol propionate at 40
g/d for 4 weeks was selected on the basis of the
randomized controlled trials conducted by the
French group.8,9 Other therapies include tetracycline
at full doses for 4 weeks; dapsone 1.5 mg/kg/d for 4
weeks; methotrexate 15 mg/wk (if[60 kg and no
major renal impairment) for 4 weeks; azathioprine
2.5mg/kg/d for 4weeks (if thiopurine s-methyltrans-
ferase level is normal); or mycophenolate mofetil 40
mg/kg/d (if normal renal function, otherwise accord-
ing to age/creatinine clearance) for 4 weeks. The
definition does not imply these drugs and their
respective doses are equivalent in therapeutic effi-
cacy. Rather it provides a standardized agreement as
to what can be defined as a failure of therapy.
BP disease activity index
Like the Pemphigus Disease Area Index (PDAI),3
the BP Disease Area Index (BPDAI) measure has
separate scores for skin and mucous membrane
activity. Damage scores are separate as well and
are included to remind physicians that not all visible
lesions in BP represent active disease. Areas of the
skin predominantly affected in BP10 were taken into
account when selecting the skin sites so that trials
would better differentiate clinical response in BP.
Hence, additional weighting was given to the arms
and legs and less emphasis to the face and scalp,
slightly different from the PDAI. The mucous mem-
brane areas were retained from the PDAI even
though it is relatively rare to see mucous membrane
involvement in BP, so that the activity could becompared with extent of mucous membrane in-
volvement in different autoimmune bullous dis-
eases. There are separate columns for the extent of
blistering and for the urticarial/eczematous lesions
that may be more extensive in BP.
As amajor symptom that may herald the onset and
recurrence of BP is pruritus, a separate subjective
component of the BPDAI is proposed to measure the
severity of this (Fig 2). Naturally, other causes of
pruritus in the elderly must be excluded, such as
xerosis, dermatitis, renal impairment, liver impair-
ment, and scabies. Providing that only pruritus
related to BP is considered in the definitions and
scored, this system can be used to subjectively grade
the intensity of pruritus using a visual analog scale to
answer the question, ‘‘How severe is your itching
today?’’ and the patient marks an ‘‘x’’ on the 0- to
10-cm linewhere0 is no itchand10 ismaximal itching.
The degree of itching is measured as the distance in
centimeters from 0, out of 10. This is repeated for the
severity overall of itching in the past week andmonth.
A total score is calculated from this out of 30. If the
patient with BP is incapable of completing a reliable
visual analog scale rating, for example, as a result of
dementia, then the degree of pruritus is inferred,
based on the extent of excoriations alone, also scored
Fig 3. Objective bullous pemphigoid disease area index
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combinedwith the objectivepart of theBPDAI (Fig 3).
Eventually, a quality-of-life tool for BP will be neces-
sary aswell. TheBPDAIwill be undergoing validation
studies, similar to the partial validation done thus far
with the PDAI.3DISCUSSION AND CONCLUSION
Despite many trials evaluating therapeutic op-
tions for BP, it has been difficult to compare the
results from these trials because of the large number
of end points and definitions of disease. The
formation of an international committee of bullous
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regular basis has provided a mechanism for devel-
oping agreement on these issues for BP. This state-
ment with agreed-upon common definitions, and
the ongoing discussion and refinement of proposed
common measurements for patients with BP, are the
initial and necessary steps toward progress in the
clinical evaluation and therapy of BP. Further pro-
gress and advancement will require a continued
unified effort.
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